文献速递间质性肺疾病

尼达尼布长期治疗特发性肺纤维化:TOMORROW试验及其开放标签扩展结果

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.
PubMed 文献 · Thorax · 2017-10-09

TOMORROW试验包含52周随机安慰剂对照期、后续盲法治疗期及开放标签扩展期。评估起始随机接受尼达尼布150 mg每日两次或安慰剂患者在各期的结局。FVC年下降率尼达尼布组为-125.4 mL/年(95% CI -168.1至-82.7),对照组为-189.7 mL/年(95% CI -229.8至-149.6)。尼达尼布不良事件特征在研究全程保持一致,结果支持尼达尼布延缓特发性肺纤维化进展的获益超过52周。

要点

  • 尼达尼布150 mg每日两次长期治疗可延缓IPF患者FVC下降。
  • FVC年下降率尼达尼布组-125.4 mL/年,对照组-189.7 mL/年。
  • 尼达尼布不良事件特征在长期治疗中保持稳定。

核心结论

  • 尼达尼布对延缓特发性肺纤维化进展的获益可超过52周。

研究设计与样本

  • TOMORROW试验包括52周随机安慰剂对照期、后续盲法治疗期及开放标签扩展期。
  • 评估起始随机接受尼达尼布150 mg每日两次或安慰剂患者在各期的结局。

主要发现

  • FVC年下降率尼达尼布组为-125.4 mL/年(95% CI -168.1至-82.7)。
  • FVC年下降率对照组为-189.7 mL/年(95% CI -229.8至-149.6)。
  • 尼达尼布不良事件特征在研究全程保持一致。

临床怎么用

  • 对特发性肺纤维化患者,可考虑长期使用尼达尼布150 mg每日两次以延缓FVC下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was -125.4 mL/year (95% CI -168.1 to -82.7) in the nintedanib group and -189.7 mL/year (95% CI -229.8 to -149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2017. PMID: 28993537. doi:10.1136/thoraxjnl-2016-209701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。